Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gossamer Bio Inc GOSS

Healthcare Biotechnology
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH). Its product candidate Seralutinib, also known as GB002, is an investigational inhaled, small molecule, platelet-derived growth factor receptor (PDGFR), colony-stimulating factor 1 receptor... see more

Recent & Breaking News (NDAQ:GOSS)

Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates

Business Wire October 12, 2020

Gossamer Bio Announces GB004 Data Presentations at United European Gastroenterology Virtual Week 2020

Business Wire October 9, 2020

Gossamer Bio Announces Participation in Upcoming Investor Conferences

Business Wire September 10, 2020

Gossamer Bio Announces Data Presentations at the Virtual European Respiratory Society International Congress 2020

Business Wire September 7, 2020

Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update

Business Wire August 11, 2020

Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12

GlobeNewswire August 10, 2020

Gossamer Bio Announces Data Presentations at the American Thoracic Society 2020 Virtual Conference

Business Wire August 5, 2020

Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma

GlobeNewswire June 8, 2020

GOSS ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 2, 2020 in the Class Action Filed on Behalf of Gossamer Bio, Inc. Limited Shareholders

Newsfile June 2, 2020

GOSS FINAL DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020

Newsfile June 2, 2020

Gossamer Deadline Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Gossamer Bio, Inc. to Contact the Firm

Newsfile June 2, 2020

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA June 2, 2020

DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile June 2, 2020

GOSS FINAL DEADLINE TODAY: Rosen, a Top Ranked Law Firm, Reminds Gossamer Bio, Inc. Investors of Important June 2 Deadline in Securities Class Action - GOSS

GlobeNewswire June 2, 2020

FINAL DEADLINE TUESDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses to Contact the Firm

ACCESSWIRE IA June 1, 2020

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Gossamer Bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of June 2, 2020 - GOSS

Newsfile June 1, 2020

DEADLINE TOMORROW: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile June 1, 2020

GOSS FINAL DEADLINE: Bronstein, Gewirtz & Grossman, LLC Reminds Gossamer Bio, Inc. Investors of Class Action and Lead Plaintiff Deadline: June 2, 2020

Newsfile June 1, 2020

Gossamer Bio Announces Participation in Upcoming Investor Conferences

Business Wire June 1, 2020

TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Gossamer Bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA May 31, 2020